Abstract 354P
Background
In Malaysia, up to 68% of cancer patients uses CAM, with CAM disclosure at only 7.6%. Perception of doctors’ poor knowledge on CAM, and non-belief in its practice are some reasons cited for non-disclosure. This may lead to various complications.
Methods
This cross-sectional study was carried out in 2 university hospitals in Malaysia from 1st July to 23rd December 2016. All doctors and nurses of Oncology Departments were included. Subjects were briefed on the study before questionnaires were distributed and returned anonymously once completed. The questionnaire was adopted with local adaptations, from a study done in Japan on perceptions and attitudes on CAM. A pilot study was done and the final validated version consists of 2 sections. Section A consists of questions on socio-demographic characteristics of respondent. Section B consisted of questions to assess the respondent’s knowledge, perception and attitude on CAM. Each question was given a point scale. Based on total points obtained, respondents were classified into good or poor knowledge, positive or negative perception and attitude towards CAM.
Results
Total of 60 nurses and 26 doctors responded, with 16 male and 70 female. Generally, all respondents have poor knowledge on CAM. Two thirds (67.4%) were not aware of the existence of the National Policy on CAM in Malaysia. Most have very little or no knowledge on the CAM modalities listed. The respondents have negative perception on CAM, with 83.7% feel the lack of evidence in its effectiveness. Most (72%) think that there is a definite or possible interaction between CAM products and anticancer drugs. All have negative attitude on CAM except 8.1% of respondents encouraging the use of CAM. Majority do not encourage the use of CAM products in both early (79.1%) and advanced (64%) stage.
Conclusions
Oncology-related healthcare providers have poor knowledge, with negative perception and attitude towards CAM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session